[1]

Zhou Y, Stevis PE, Cao J, Saotome K, Wu J, et al. 2023. Structural insights into the assembly of gp130 family cytokine signaling complexes. Science Advances 9:eade4395

doi: 10.1126/sciadv.ade4395
[2]

Xu Y, Kershaw NJ, Luo CS, Soo P, Pocock MJ, et al. 2010. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. Journal of Biological Chemistry 285:21214−21218

doi: 10.1074/jbc.C110.129502
[3]

Fang L, Liu K, Liu C, Wang X, Ma W, et al. 2022. Tumor accomplice: T cell exhaustion induced by chronic inflammation. Frontiers in Immunology 13:979116

doi: 10.3389/fimmu.2022.979116
[4]

Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. 2023. Targeting IL-6 trans-signalling: past, present and future prospects. Nature Reviews Immunology 23:666−681

doi: 10.1038/s41577-023-00856-y
[5]

Rose-John S. 2021. Therapeutic targeting of IL-6 trans-signaling. Cytokine 144:155577

doi: 10.1016/j.cyto.2021.155577
[6]

Li H, Xiao H, Lin L, Jou D, Kumari V, et al. 2014. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. Journal of Medicinal Chemistry 57:632−641

doi: 10.1021/jm401144z
[7]

Saleh AZM, Greenman KL, Billings S, Van Vranken DL, Krolewski JJ. 2005. Binding of madindoline A to the extracellular domain of gp130. Biochemistry 44:10822−10827

doi: 10.1021/bi050439+
[8]

Hong SS, Choi JH, Lee SY, Park YH, Park KY, et al. 2015. A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130. The Journal of Immunology 195:237−245

doi: 10.4049/jimmunol.1402908
[9]

Park YH, Jang YJ, Choi Y, Lee K, Kim HJ, et al. 2021. Combination of LMT-28 and metformin improves beneficial anti-inflammatory effect in collagen-induced arthritis. Pharmacology 106:53−59

doi: 10.1159/000507451
[10]

Xu S, Grande F, Garofalo A, Neamati N. 2013. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics 12:937−949

doi: 10.1158/1535-7163.MCT-12-1082
[11]

Pozios I, Hering NA, Guenzler E, Arndt M, Elezkurtaj S, et al. 2023. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Journal of Cancer Research and Clinical Oncology 149:271−280

doi: 10.1007/s00432-022-04518-9
[12]

Wu P, Liang X, Wang H, Wang Z, Niu Y, et al. 2024. Structurally diverse design and synthesis of novel 2-phenylindole amide derivatives with anti-canine breast cancer activity. Bioorganic Chemistry 153:107788

doi: 10.1016/j.bioorg.2024.107788
[13]

Park SA, Kim LK, Park HM, Kim HJ, Heo TH. 2022. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer. Oncology Reports 47:1−14

doi: 10.3892/or.2022.8263
[14]

Kim L, Park SA, Park H, Kim H, Heo TH. 2021. Bazedoxifene, a GP130 inhibitor, modulates EMT signaling and exhibits antitumor effects in HPV-positive cervical cancer. International Journal of Molecular Sciences 22:8693

doi: 10.3390/ijms22168693
[15]

Song D, Yu W, Ren Y, Zhu J, Wan C, et al. 2020. Discovery of bazedoxifene analogues targeting glycoprotein 130. European Journal of Medicinal Chemistry 199:112375

doi: 10.1016/j.ejmech.2020.112375
[16]

Dhall A, Patiyal S, Sharma N, Devi NL, Raghava GPS. 2021. Computer-aided prediction of inhibitors against STAT3 for managing COVID-19 associated cytokine storm. Computers in Biology and Medicine 137:104780

doi: 10.1016/j.compbiomed.2021.104780
[17]

Singh S, Gajulapati V, Gajulapati K, Goo JI, Park YH, et al. 2016. Structure–activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers. Bioorganic & Medicinal Chemistry Letters 26:1282−1286

doi: 10.1016/j.bmcl.2016.01.016
[18]

Wei J, Ma L, Lai YH, Zhang R, Li H, et al. 2019. Bazedoxifene as a novel GP130 inhibitor for colon cancer therapy. Journal of Experimental & Clinical Cancer Research 38:63

doi: 10.1186/s13046-019-1072-8
[19]

Lim HJ, Jang HJ, Bak SG, Lee S, Lee SW, et al. 2019. In vitro inhibitory effects of cirsiliol on IL-6-induced STAT3 activation through anti-inflammatory activity. Bioorganic & Medicinal Chemistry Letters 29:1586−1592

doi: 10.1016/j.bmcl.2019.04.053
[20]

Wu X, Cao Y, Xiao H, Li C, Lin J. 2016. Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy. Molecular Cancer Therapeutics 15:2609−2619

doi: 10.1158/1535-7163.MCT-15-0921
[21]

Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, et al. 2002. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proceedings of the National Academy of Sciences of the United States of America 99:14728−14733

doi: 10.1073/pnas.232562799
[22]

Fu L, Shi S, Yi J, Wang N, He Y, et al. 2024. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Research 52:W422−W431

doi: 10.1093/nar/gkae236
[23]

Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, et al. 2011. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorganic & Medicinal Chemistry 19:1823−1838

doi: 10.1016/j.bmc.2010.12.010
[24]

Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey VN, et al. 2008. STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Molecular Cancer Therapeutics 7:1543−1550

doi: 10.1158/1535-7163.MCT-08-0154
[25]

Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, et al. 2020. A deep learning approach to antibiotic discovery. Cell 180:688−702.e13

doi: 10.1016/j.cell.2020.01.021
[26]

Yang K, Swanson K, Jin W, Coley C, Eiden P, et al. 2019. Analyzing learned molecular representations for property prediction. Journal of Chemical Information and Modeling 59:3370−3388

doi: 10.1021/acs.jcim.9b00237
[27]

Zhang Y, Zhang Y, Zhao Y, Wu W, Meng W, et al. 2022. Protection against ulcerative colitis and colorectal cancer by evodiamine via anti-inflammatory effects. Molecular Medicine Reports 25:1−14

doi: 10.3892/mmr.2022.12704
[28]

Lu Y, Dong K, Yang M, Liu J. 2023. Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer. BMC Complementary Medicine and Therapies 23:433

doi: 10.1186/s12906-023-04254-8
[29]

Schillinger O, Panwalkar V, Strodel B, Dingley AJ. 2017. Molecular dynamics simulations reveal key roles of the interleukin-6 alpha receptor in the assembly of the human interleukin-6 receptor complex. The Journal of Physical Chemistry B 121:8113−8122

doi: 10.1021/acs.jpcb.7b05732
[30]

Johnson DE, O’Keefe RA, Grandis JR. 2018. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology 15:234−248

doi: 10.1038/nrclinonc.2018.8
[31]

Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19:2474−2488

doi: 10.1038/sj.onc.1203527
[32]

Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285:1−24

doi: 10.1016/s0378-1119(02)00398-0
[33]

Carneiro BA, El-Deiry WS. 2020. Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology 17:395−417

doi: 10.1038/s41571-020-0341-y
[34]

Xu S, Neamati N. 2013. gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets 17:1303−1328

doi: 10.1517/14728222.2013.830105
[35]

Liu QQ, Wu WW, Yang J, Wang RB, Yuan LL, et al. 2023. A GP130-targeting small molecule, LMT-28, reduces LPS-induced bone resorption around implants in diabetic models by inhibiting IL-6/GP130/JAK2/STAT3 signaling. Mediators of Inflammation 2023:1−14

doi: 10.1155/2023/9330439
[36]

Osman EEA, Neamati N. 2024. Ironing out the mechanism of gp130 signaling. Pharmacological Reviews 76:1399−1443

doi: 10.1124/pharmrev.124.001245
[37]

Pant A, Brahim Belhaouari D, Dsouza L, Priyamvada L, Wang Z, et al. 2025. Suppression of poxvirus replication by SC144. Antiviral Research 240:106204

doi: 10.1016/j.antiviral.2025.106204
[38]

Hibi M, Murakami M, Saito M, Hirano T, Taga T, et al. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149−1157

doi: 10.1016/0092-8674(90)90411-7
[39]

Morris VA, Punjabi AS, Lagunoff M. 2008. Activation of Akt through gp130 receptor signaling is required for Kaposi’s sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells. Journal of Virology 82:8771−8779

doi: 10.1128/JVI.00766-08
[40]

He Y, Zhou H, Qu Y, Chi R, Xu H, et al. 2024. Pharmacological modulation of gp130 signalling enhances Achilles tendon repair by regulating tenocyte migration and collagen synthesis via SHP2-mediated crosstalk of the ERK/AKT pathway. Biochemical Pharmacology 226:116370

doi: 10.1016/j.bcp.2024.116370
[41]

Fahmi A, Smart N, Punn A, Jabr R, Marber M, et al. 2013. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cellular Signalling 25:898−909

doi: 10.1016/j.cellsig.2012.12.008
[42]

Taga T. 1996. Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Journal of Neurochemistry 67:1−10

doi: 10.1046/j.1471-4159.1996.67010001.x